- Volume 17 Issue 3
Background: The aim of this study is to compare the numbers of axillary lymph nodes (ALN) taken out by dissection between patients with breast cancer operated on after having neoadjuvant chemotherapy (NAC) treatment and otherswithout having neoadjuvant chemotherapy, and to investigate factors affecting lymph node positivity. Materials and Methods: A total of 49 patients operated due to advanced breast cancer after neoadjuvant chemotherapy and 144 patients with a similar stage of the cancer having primary surgical treatment without chemotherapy at the general surgery clinic of Ondokuz Mayis University Medicine Faculty between the dates 01.01.2006 and 31.10.2012 were included in the study. The total number of lymph nodes taken out by axillary dissection (ALND) was categorized as the number of positive lymph nodes and divided into <10 and
Breast cancer;neoadjuvant chemotherapy;axillary lymph nodes;dissection
- Apffelstaedt JP (2003). Locally advanced breast cancer in developing countries: the place of surgery. World J Surg, 27, 917-20. https://doi.org/10.1007/s00268-003-6974-z
- Belanger J, Soucy G, Sideris L, et al (2008). Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg, 206, 704-8. https://doi.org/10.1016/j.jamcollsurg.2007.10.016
- Boughey JC, Mc Call LM, Ballman KV, et al (2014). Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg, 260. 608-14 https://doi.org/10.1097/SLA.0000000000000924
- Brotherick I, Shenton BK, CoWan WK, et al (1995). The relationship between flow-cytometric and immunohistochemically detected c-erbB2 expression, grade and DNA ploidy in breast cancer. Cancer Immunol Immunother, 41, 137-45. https://doi.org/10.1007/BF01521338
- Chaves-Mac Gregor M, Gonzalez-Angulo AM, (2010). Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Trans Oncol, 12, 461-7. https://doi.org/10.1007/s12094-010-0538-0
- Clark GM, McGuire WL (1988). Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol, 15-20.
- Colleoni M, Minchella I, Mazzarol G, et al (2000). Response to primary chemotherapy in breast cancer patients with tumours not expressing estrogen and progesterone receptors. Ann Oncol, 11, 1057-9. https://doi.org/10.1023/A:1008334404825
- Giani C, Campani D, De Negri F, et al (1989). Relationship between progesterone receptor, axillary node status and productive fibrosis in ductal infiltrating carcinoma of the breast. Appl Pathol, 7, 225-32.
- Goel S, Chirgwin J, Francis P, et al (2011). Rational use of transtuzumab in metastatic and locally advanced breast cancer; implications of recent research. Breast, 20, 101-10. https://doi.org/10.1016/j.breast.2010.11.008
- Gogia A, Raina V, Deo SV, et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev, 15, 1989-92. https://doi.org/10.7314/APJCP.2014.15.5.1989
- Greene FL, Page DL, Fleming ID (2002). AJCC Cancer Staging Manual, 6th Edition, New York,Springer-Verlag, 227-8.
- Keam B, Im SA, Lim Y, et al (2013). Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. Ann Surg Oncol, 11, 435-41.
- Khokher S, Mahmood S, Khan SA (2010). Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience. Asian Pac J Cancer Prev, 11, 303-8.
- Knight WA, Livinston RB, Gregory FJ, et al (1977). Estrogen receptor as an independent prognostic factor for early reccurence in breast cancer. Cancer Res, 37, 46-69.
- Kuerer HM, Newman LA, Buzdar AU, et al (1998). Pathologic tumor responce in breast following neoadjuvant chemotherapypredicts axillarylymph node status. Cancer J Sci Am, 4, 230-6.
- Kurio K, Toi M, Tsuda H, et al (2006). Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer, 13, 38-48. https://doi.org/10.2325/jbcs.13.38
- Makris A, Powles TJ, Dowsett M, et al (1997).Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res, 3, 593-600.
- Neuman H, Carey LA, Ollila DW, et al (2006). Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg, 191, 827-9. https://doi.org/10.1016/j.amjsurg.2005.08.041
- Rahusen FD, Torrenga H, van Diest PJ, et al (2001). Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg, 136, 1059-63. https://doi.org/10.1001/archsurg.136.9.1059
- Schaapveld M, Otter R, De Vries EG et al (2004). Variability in axillary lymph node dissection for breast cancer. J Surg Oncol, 87, 4-12. https://doi.org/10.1002/jso.20061
- Somner JE, Dixon JM, Thomas JS (2004). Node retrival in axillary lymph node dissection: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol, 57, 845-8. https://doi.org/10.1136/jcp.2003.015560
- Thain SK, Olivotto IA, Bouchard F, et al (1998). Axillary dissection.The steering committee on clinical practice guidilines for the care and treatment of breast cancer. Can Med Assoc J, 10. 158.
- Yu Y, Xiang H, He XM, et al (2013). Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience. Asian Pac J Cancer Prev, 14, 2401-6. https://doi.org/10.7314/APJCP.2013.14.4.2401
- Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study vol.9, pp.6, 2018, https://doi.org/10.1111/1759-7714.12636